Vectus Biosystems Ltd
VBS
Company Profile
Business description
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including cardio, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
Contact
26-34 Dunning Avenue
Unit 5, Ground Floor
Rosebery
SydneyNSW2018
AUST: +61 283441300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
This defensive ASX listed REIT offers a 5% yield
Solid outlook underpinned by rent uplifts and development pipeline.
stocks
Chart of the Week: Anthropic’s IPO range sits below our fair value
Our fair value is above the IPO range, but outcomes could differ widely.
stocks
Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released
Several gaming shares are trading at a discount to our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,833.10 | 99.30 | -1.11% |
| CAC 40 | 8,146.83 | 69.95 | -0.85% |
| DAX 40 | 25,736.24 | 309.13 | -1.19% |
| Dow JONES (US) | 50,198.17 | 561.25 | -1.11% |
| FTSE 100 | 10,551.17 | 138.70 | -1.30% |
| HKSE | 22,858.54 | 436.21 | -1.87% |
| NASDAQ | 24,429.88 | 101.50 | 0.42% |
| Nikkei 225 | 59,304.05 | 279.77 | 0.47% |
| NZX 50 Index | 14,247.25 | 17.04 | -0.12% |
| S&P 500 | 7,323.63 | 16.90 | -0.23% |
| S&P/ASX 200 | 8,726.50 | 95.30 | -1.08% |
| SSE Composite Index | 3,576.02 | 11.81 | -0.33% |